The Archipelago Ubiquitin Ligase Subunit Acts in Target Tissue to Restrict Tracheal Terminal Cell Branching and Hypoxic-Induced Gene Expression

Nathan T. Mortimer, Emory University
Kenneth H Moberg, Emory University

Journal Title: PLoS Genetics
Volume: Volume 9, Number 2
Publisher: Public Library of Science | 2013-02-14, Pages 1-11
Type of Work: Article | Final Publisher PDF
Publisher DOI: 10.1371/journal.pgen.1003314
Permanent URL: http://pid.emory.edu/ark:/25593/f71xr

Final published version: http://www.plosgenetics.org/article/info\%3Adoi\%2F10.1371\%2Fjournal.pgen.1003314

Copyright information:
© 2013 Mortimer and Moberg.
This is an Open Access work distributed under the terms of the Creative Commons Attribution 2.5 Generic License (http://creativecommons.org/licenses/by/2.5/).

Accessed December 6, 2018 8:02 PM EST
The *Archipelago* Ubiquitin Ligase Subunit Acts in Target Tissue to Restrict Tracheal Terminal Cell Branching and Hypoxic-Induced Gene Expression

Nathan T. Mortimer*, Kenneth H. Moberg*

Department of Cell Biology, Emory University School of Medicine, Atlanta, Georgia, United States of America

Abstract

The *Drosophila melanogaster* gene *archipelago* (*ago*) encodes the F-box/WD-repeat protein substrate specificity factor for an SCF (Skp/Cullin/F-box)-type polyubiquitin ligase that inhibits tumor-like growth by targeting proteins for degradation by the proteasome. The *ago* protein is expressed widely in the fly embryo and larva and promotes degradation of pro-proliferative proteins in mitotically active cells. However, the requirement for *ago* in post-mitotic developmental processes remains largely unexplored. Here we show that *ago* is an antagonist of the physiologic response to low oxygen (hypoxia). Reducing *ago* activity in larval muscle cells elicits enhanced branching of nearby tracheal terminal cells in normoxia. This tracheogenic phenotype shows a genetic dependence on *sima*, which encodes the HIF–1α subunit of the hypoxia-inducible transcription factor dHIF and its target the FGF ligand *branchless* (*bnl*), and is enhanced by depletion of the *Drosophila* Von Hippel Lindau (*dVHL*) factor, which is a subunit of an oxygen-dependent ubiquitin ligase that degrades Sima/HIF–1α protein in metazoan cells. Genetic reduction of *ago* results in constitutive expression of some hypoxia-inducible genes in normoxia, increases the sensitivity of others to mild hypoxic stimuli, and enhances the ability of adult flies to recover from hypoxic stupor. As a molecular correlate to these genetic data, we find that *ago* physically associates with Sima and restricts Sima activities in vivo. Collectively, these findings identify *ago* as a required element of a circuit that suppresses the tracheogenic activity of larval muscle cells by antagonizing the Sima-mediated transcriptional response to hypoxia.

Introduction

Metabolically active tissues require an adequate supply of dioxygen (O$_2$) for metabolic production of ATP by aerobic glycolysis and as a necessary substrate in a variety of enzymatic reactions [reviewed in [1]]. Consequently, cells in metazoan organisms have evolved a conserved hypoxia-response mechanism that senses low O$_2$ (or hypoxia) and modulates cellular metabolism and signaling in response to this environmental challenge. Activation of this adaptive mechanism results in changes in transcription that allow organisms to adapt to O$_2$ conditions [4–7] and is regulated mainly at the level of HIF–1α [8,9] and *tango* (*tgo*) [10–12] genes. The HIF–1α/dHIF heterodimer is required for cellular adaptation to hypoxic conditions and is regulated mainly at the level of HIF–1α stability [reviewed in [13]]. In normoxic conditions, HIF–1α is hydroxylated at conserved proline residues by the 2-oxoglutarate/Fe(II)-dependent prolyl-4-hydroxylase family member HIF prolyl hydroxylase (HPH) [14,15]. Prolyl-hydroxylation of HIF–1α facilitates binding with the von Hippel Lindau (VHL) E3-ubiquitin ligase subunit, and subsequent polyubiquitination and proteasome-dependent degradation of HIF–1α [16–20]. *Drosophila* Sima is controlled by a well-conserved version of this pathway involving the HPH homolog *fatiga* (*fg*), and the *Drosophila* VHL homolog, *dVHL* [14,21–24]. Because the HPH enzymatic activity is dependent upon the availability of oxygen [14,15], the HPH/VHL pathway effectively functions as a sensor of cellular oxygen levels, allowing HIF–1α/Sima stabilization only in hypoxic conditions and preventing HIF activity in normoxic cells [reviewed...
Author Summary

Cells in multicellular animals must adapt to changing environmental conditions in order to ensure survival of the larger organism. One key challenge they face is fluctuation in the availability of dissolved oxygen. As cells get low on oxygen, they respond by turning on a program of gene expression that helps them survive. The key to this program is a protein, called HIF-1α, that helps cells "think" they are hypoxic. This finding and the data that support it provide new insight into genetic circuits that control their response to changing oxygen levels and suggest that defects in oxygen homeostasis may contribute to cancerous disease states associated with loss of the human equivalent of Archipelago called Fbw7.

in 2]. Mutations in the VHL gene stabilize HIF-1α and are associated with a dominantly inherited hereditary cancer syndrome in humans that predisposes to a variety of malignant and benign tumors of the eye, brain, spinal cord, kidney, pancreas, and adrenal glands [25]. Excess HIF-1α can promote several important aspects of cancer biology, including the metabolic switch to anaerobic glycolysis characteristic of tumor cells [i.e. the Warburg effect; 26], neoangiogenesis, and increased tumor metastasis [reviewed in 13,27,28].

The invertebrate response to hypoxia mirrors key features of the mammalian hypoxic response [3,29,30]. Hypoxia stabilizes Sima and induces expression of genes that include homologs of mammalian HIF targets, such as lactate dehydrogenase (LDH) [31]. Hypoxic treatment of flies also produces physiological changes reminiscent of the mammalian hypoxic response [32], including altered metabolism and reduced oxygen consumption [33–36]. Adult Drosophila respond to hypoxia by entering into state of stupor characterized by low or undetectable neurological activity that allows them to tolerate extended periods of low oxygen [34], and recovery from this state is dependent upon genes necessary for survival in low-oxygen conditions [31–33,35]. Hypoxia also induces a neoangiogenesis-like process in Drosophila involving increased branching of the tracheal system, an open network of interconnected, epithelial tubes that duct gases in and out of the animal [reviewed in 37]. Drosophila larvae reared in chronic hypoxia show increased branching of cells at the tip of each tracheal branch termed ‘terminal tip’ cells, whereas those raised in chronic hyperoxia show a reciprocal decrease in the extent of terminal branch elaboration [22,38]. This increased larval tracheal branching in low O2 involves the FGF receptor homolog breathless (btl) [39] and the FGF ligand branchless (bnl) [40]; hypoxic exposure results in a sima-dependent increase in expression of btl in tracheal cells and bnl in peripheral oxygen-deficient tissues [22,38]. Bnl then acts on tracheal terminal tip cells, which express Btl [41,42], to induce fine tubular extensions that project toward Bul-expressing cells. These terminal branches serve as the primary site of gas exchange between the tracheal system and internal tissues. When the oxygen demand is met, Bnl and Btl expression decreases, thereby limiting hypoxia-induced tracheal growth. This oxygen responsiveness allows for growth of tracheal terminal branches specifically to localized areas of hypoxia in order to shape the mature tracheal architecture and to increase oxygen-delivery capacity in hypoxic conditions.

In addition to the oxygen-dependent HPH/VHL pathway, mammalian HIF-1 is regulated by VHL-independent mechanisms that are incompletely understood [43,44]. Recent studies have linked HIF–1α turnover to phosphorylation by the GSK3β kinase and subsequent binding of the ubiquitin ligase subunit Fbw7 [43,46], which is a sequence and functional ortholog of the Drosophila Archipelago (Ago) protein. Intriguingly Drosophila Ago binds and stimulates turnover of the Trachealess protein (Tbr), which is a Sima/HIF-1α sequence homolog, in embryonic tracheal cells [47]. Genetic data show ago and dVHL also coregulate oxygen-sensitivity in the developing embryonic tracheal arbor [48].

In light of these connections, we have tested the requirement for ago in oxygen-sensitive stages of larval tracheal development and find evidence that ago is an antagonist of dHIF during the larval stage. Genetic manipulations that reduce ago activity in the dHIF target genes in normoxia, increases the sensitivity of others to mild hypoxic stimulus, and allows adult flies to recover more rapidly from hypoxic stuper than normal flies. Significantly, non-cell autonomous effects of ago and dVHL alleles on terminal branching are synergistic, suggesting that the Ago and dVHL proteins co-regulate dHIF. Consistent with this, Ago protein can be found in a complex with Sima in larval extracts and loss of Ago elevates Sima levels in peripheral tissues. Collectively these findings define an important role for Ago as a required antagonist of the Sima-dependent hypoxic response during the larval stage of Drosophila development.

Results

Loss of ago results in increased branching of tracheal terminal cells

Heterozygosity for a null allele of ago sensitizes the Drosophila embryonic tracheal system to mild hypoxia [48]. To determine whether ago is also involved in hypoxia responsiveness in the subsequent larval stage, it was necessary to generate an allele of ago that allowed development beyond the late embryonic lethality associated with ago null alleles [49]. This was achieved by transposase-mediated imprecise excision of EP(3)1135, a P-element located 16 base pairs (bp) upstream of the ago genomic locus [Bloomington Drosophila Stock Center (BDSC)] that behaves genetically as a weak ago hypomorph. Excision of EP(3)1135 produced a 603 bp deletion removing the first exon of the ago-RC transcript (Figure 1A–1B) that was designated ago-β3–7. The effect of ago-β3–7 on patterns of ago transcription was determined by quantitative real-time PCR (qRT-PCR). Of the three predicted ago transcripts (ago-RA, ago-RB, and ago-RC) only RC and RC are detected in whole larvae (Figure 1C). Consistent with the location of the deletion in the ago-β3–7 allele, the ago-RC transcript is specifically absent in ago-β3–7 mutant larvae while expression of the ago-RC transcript is unaffected. Notably, the ago-RA and RC transcripts display inverse expression patterns: ago-RA is approximately 3-fold more abundant than ago-RC in imaginal...
discs and larval brain and ventral nerve cord, but ago-RC is 3-fold more abundant than ago-RA in filleted larval body wall preparations (Figure 1D). The agoA3–7 allele is thus a tissue- and transcript-specific allele that primarily reduces ago expression in peripheral tissues such as body wall muscle.

Approximately 49% of agoA3–7 homozygotes or trans-heterozygotes in combination with the null alleles ago1 and ago3 die as pupae (Table 1) and the remainder die as late 3rd and 4th instar larvae (data not shown). Those that live to late 3rd instar show tracheal phenotypes (Figure 2 and Table 2). The most prevalent of these phenotypes is an approximate doubling of the number of cytoplasmic branches elaborated from multiple subtypes of terminal cells, including those found along the lateral trunk that serve to oxygenate the ventrolateral body wall muscles: LH cell terminal branching increases from 20.4 ± 0.64 branches (n = 33) in control larvae to 39.5 ± 1.59 branches (n = 34) in agoA3–7/1 larvae (p = 2.6 × 10−16) (Figure 2A–2C and Table 2), and LG cell terminal branching increases from 19.6 ± 0.54 branches (n = 33) in control larvae to 36.8 ± 1.94 branches (n = 31) in agoA3–7/1 larvae (p = 9.5 × 10−13) (Figure 2C). Notably, the magnitude of these increases in terminal cell branch number is similar to that seen in larvae grown in hypoxic conditions [22,23]. Loss of ago function also causes additional tracheal branch phenotypes in approximately 25% of larvae, including the appearance of ringlet-shaped branches and tangles (Figure 2D) and the development of ‘ringlet’-shaped ganglionic branches (Figure 2F), which resemble phenotypes seen in hypoxic larvae or those in which Sima is activated by genetic disruption of the Fga/dVHL regulatory pathway [22]. Given the transcript- and tissue-specific nature of the agoA3–7 allele, these tracheal phenotypes support the hypothesis that ago has a non-autonomous role in restricting terminal branching.

Table 1. Pre-pupal lethality of ago allele combinations. 

<table>
<thead>
<tr>
<th>Genotype</th>
<th>% observed (± SEM)</th>
<th>n</th>
</tr>
</thead>
<tbody>
<tr>
<td>agoA3–7</td>
<td>49.8 ± 3.26</td>
<td>983</td>
</tr>
<tr>
<td>agoA3–7 ago1</td>
<td>77.4 ± 7.61</td>
<td>1056</td>
</tr>
<tr>
<td>agoA3–7 ago3</td>
<td>67.7 ± 5.17</td>
<td>1680</td>
</tr>
<tr>
<td>agoA3–7 simA77007</td>
<td>43.2 ± 5.25</td>
<td>1153</td>
</tr>
<tr>
<td>agoA3–7 simA77007</td>
<td>71.0 ± 7.82</td>
<td>878</td>
</tr>
</tbody>
</table>

*Calculated as # observed/# expected.

p<0.05 relative to

**agoA3–7,

**agoA3–7/1,

**agoA3–7/3.

doi:10.1371/journal.pgen.1003314.t001

Table 2. Number of tracheal terminal branches per LH cell.

<table>
<thead>
<tr>
<th>Genotype</th>
<th># branches/LH cell (± SEM)</th>
<th>n</th>
</tr>
</thead>
<tbody>
<tr>
<td>wt</td>
<td>20.4 ± 0.64</td>
<td>33</td>
</tr>
<tr>
<td>agoA3–7/1</td>
<td>39.5 ± 1.59</td>
<td>34</td>
</tr>
<tr>
<td>agoA3–7 simA77007</td>
<td>28.0 ± 1.48</td>
<td>34</td>
</tr>
<tr>
<td>agoA3–7 simA77007</td>
<td>28.4 ± 1.80</td>
<td>29</td>
</tr>
<tr>
<td>agoA3–7/1</td>
<td>42.2 ± 2.94</td>
<td>6</td>
</tr>
<tr>
<td>agoA3–7 simA77007</td>
<td>26.1 ± 1.62</td>
<td>16</td>
</tr>
</tbody>
</table>

p<1.0 × 10−4 relative to

**wt,

**agoA3–7,

**agoA3–7/1,

**agoA3–7/3.

doi:10.1371/journal.pgen.1003314.t002

Figure 1. The agoA3–7 allele specifically deletes the ago-RC transcript, which is enriched in body wall muscle cells. (A) Graphical representation of the ago genomic locus illustrating the three ago transcripts and the alleles used in this study. (B) Genomic PCR to confirm the agoA3–7 deletion. (C) Quantification of the relative transcription of the three ago transcripts in larvae in the indicated genotypes by quantitative real-time PCR (qRT-PCR). (*p < 0.05 relative to control). (D) Tissue specific qRT-PCR of the indicated ago transcripts to assay relative abundance in the indicated tissues. doi:10.1371/journal.pgen.1003314.g001

Figure 2. agoA3–7/1 larvae display a wide range of tracheal terminal branch phenotypes. (A,B) Schematic (left) and representative photomicrograph showing branching of LH lateral terminal cells in control (A) and agoA3–7/1 (B) larvae. Branch termini are indicated with asterisks. (C) Quantification of branch number per LH (left) and LG (right) terminal cell in the indicated genotypes (*p<0.001 relative to control). (D) agoA3–7/1 larva displaying terminal branch tangling. (E,F) Ganglionic tracheal branches in control (E) and agoA3–7/1 (F) larvae. Ringlet-shaped branches and tangles occur in approximately 25% of agoA3–7/1 larvae. doi:10.1371/journal.pgen.1003314.g002
**ago** acts non-autonomously to restrict post-embryonic tracheal branching

Although the **ago**A3-711 larval phenotypes are reminiscent of hypoxia-induced tracheal growth, they do not exclude the possibility that an earlier developmental requirement for **ago** (e.g. in the embryo) affects later branching events in the larva. To test the temporal requirement for **ago** in regulating tracheal terminal branching patterns, a dominant negative **ago** transgene (UAS-agoΔF) [47,50] was combined with the hs-Gal4 driver to produce animals in which **ago** activity could be antagonized at later developmental stages by application of a heat-shock. Whereas control and hs>agoΔF larvae show similar LH cell branch number prior to transgene induction (22.2±0.69 branches [n = 27] vs 21.7±0.69 branches [n = 24]), administration of a transient heat-shock to hs>agoΔF larvae is sufficient to drive an increase in terminal branching throughout the tracheal system (effects on LG and LH cells quantified in Figure 3A and 3B). LH cell branching is increased 24 hrs post heat-shock in both LG and LH cells quantified in Figure 3A and 3B. LH cell branching is terminal branching throughout the tracheal system (effects on LG and LH cells quantified in Figure 3A and 3B). LH cell branching is increased 24 hrs post heat-shock in both LG and LH cells (effects on LG and BH cells quantified in Figure 3A and 3B). LH cell branching is terminal branching throughout the tracheal system (effects on LG and LH cells quantified in Figure 3A and 3B). LH cell branching is increased 24 hrs post heat-shock in both LG and LH cells (effects on LG and BH cells quantified in Figure 3A and 3B).

Excess terminal branch phenotypes in hs>agoΔF and agoA3-7 animals may reflect a requirement for **ago** in either tracheal or non-tracheal cell types. To directly test whether **ago** activity is required in non-tracheal tissue to restrict branching, the agoΔF transgene was driven with the 5053A-Gal4 driver (5053A>agoΔF), which is expressed specifically in ventrolateral body wall muscle 12 (VLM12) and has been used to study non-cell autonomous tracheogenic activity of the Bul/Bul pathway [30]. The VLM12 muscle expresses endogenous, nuclear Ago protein (Figure 4G–4D) and is normally tracheated by the LF and LH cells (Figure 4A). The 5053A>agoΔF genotype approximately doubles the number of LF and LH tracheal branches that terminate on VLM12 (Figure 4B) relative to either the adjacent muscle (VLM13) or to control larvae expressing a nuclear-localized GFP (nlsGFP) (5.1±0.16 branches [n = 34] in control vs 9.5±0.29 branches [n = 30] in agoΔF, p = 4.67x10^-24 (Table 3)). This degree of excess branching produced by muscle-specific expression of the agoΔF transgene is similar to that produced by organism-wide depletion of the Ago-RC isoform with the agoA3-7 genomic allele. These combined genetic data provide evidence that Ago is required within larval body wall muscle cells to restrict the post-embryonic branching of nearby tracheal terminal cells.

**Muscle expression of Ago targets**

**ago** mutations lead to tissue-specific activation of factors normally degraded by the SCF-Ago ubiquitin ligase, including the proliferative proteins CycE and dMyc in larval imaginal discs [49,50] and the transcription factor Tracheless in tracheal cells [47]. Although the expression patterns of these proteins in body wall muscle are not well defined, we wished to test whether ectopic expression of CycE, dMyc, Trh, or the SCF-Flw7 target Notch [reviewed in 51] was even capable of conferring a non-cell autonomous tracheogenic activity to VLM12. To this end, each of these factors was individually overexpressed using the 5053A-Gal4 driver (Table 3). Muscle-specific expression of trh or Notch failed to stimulate excess terminal branch growth. The inability of trh to affect tracheal recruitment to VLM12 contrasts with its ability to phenotype ago mutant phenotypes in the embryonic trachea [47] and further suggests that the **ago** larval tracheal role is separable from its embryonic role. Muscle-specific expression of dMyc also had no effect on the degree of terminal cell branching, despite a 28.5% increase in the 2-dimensional size of the VLM12 muscle (Table 4). Notably, increased tracheation of VLM12 driven by agoΔF occurs without an increase in the size of the VLM12 muscle, which is consistent with no role for post-mitotic growth in this phenotype (Table 4). 5053A>cycE does increase terminal

---

**Figure 3.** Heat shock induction of **ago**-ΔF in larvae reveals a post-embryonic role for **ago** in restricting terminal branching. (A,B) Schematic (left) and representative photomicrograph depiction of LG lateral terminal cell branches in control (A) and hs-Gal4/UAS-agoΔF (B) larvae. Main LG branches are indicated with black arrows, extra branches in hs-Gal4/UAS-agoΔF are indicated with white arrows. (C) Quantification of the number of branches per LH terminal cell in the indicated genotypes before (left) and after (right) heat shock treatment (* p<3.0x10^-14 relative to heat shocked control). doi:10.1371/journal.pgen.1003314.g003

**Figure 4.** **ago** acts non-tracheal cell autonomously to regulate terminal branching. (A,B) Schematic (left) and representative photomicrograph depiction of LH and LF lateral terminal cell branch termini on VLM12 in 5053A-Gal4/UAS-nlsGFP control (A) and 5053A-Gal4/UAS-nlsGFP, UAS-agoΔF (B) larvae. Terminal branches terminating on VLM12 are indicated by asterisks. Arrowheads mark terminal branches with termini on other body wall muscles. (C,D) Immunofluorescence with anti-Ago antisera shows that Ago is expressed in nuclei of VLM12 (C) as marked by expression of nlsGFP (D) in 5053A-Gal4/UAS-nlsGFP larvae. doi:10.1371/journal.pgen.1003314.g004
branch number, although to a lesser degree than agoΔF. However, CycE protein levels are not obviously affected by expression of agoΔF (Figure S1), suggesting that deregulated CycE is an unlikely cause of the non-autonomous effect of ago alleles on terminal cell branching.

**ago restricts dHIF activity and bnl expression in larvae**

The similarity of ago mutant terminal branching phenotypes to those induced by hypoxia suggests that ago may antagonize the dHIF pathway. To test the genetic relationship between ago and sima in larval branchal phenotypes, the sima^{07607} loss-of-function allele [23] was introduced into the 5053A->agoΔF and ago^{AX-7}11 genetic backgrounds. Heterozygosity for sima (i.e. sima^{07607+/+}) dominantly suppressed the agoΔF VLM12 phenotype (Table 3) by decreasing terminal branch number from 5.94±0.29 (n = 50) to 6.34±0.27 branches (n = 53, p = 4.18×10^{-12}), and also suppressed the excess and overlapping terminal branching seen in ago^{AX-7}11 larvae (Table 2 and Figure 5A–5B; white arrow in A indicates a ringlet-shaped ganglionic branch) from 39.5±1.59 (n = 34) to 29.0±1.48 branches per LH cell (n = 34, p = 7.45×10^{-8}). In addition, the sima^{07607} allele dominantly delayed the lethal phase of both ago^{AX-7} homozygotes and ago^{AX-7/11} or ago^{AX-7/15} transheterozygotes (Table 1). Reciprocally, ectopic expression of sima in the VLM12 muscle (3053A->simahomozygotes and 3053A->simain heterozygotes) increased tracheal recruitment in normoxic conditions (Table 3). Muscle cells are thus distinct from ectodermal cells, which do not recruit branching following overexpression of sima [22].

To more directly assess dHIF activity in ago mutant animals, the transcription of the Drosophila LDH gene (dLDH) was measured in the body wall muscle of ago^{AX-7} and control larvae. LDH is a well-validated HIF target in vertebrates and invertebrates, and HIF-responsive elements from the LDH promoter have been used as the basis of HIF activity reporters in many different systems including Drosophila [e.g. 24]. This analysis showed a 27.3-fold increase in dLDH transcription in ago mutant larval body wall muscle preparations but no equivalent upregulation in steady-state levels of the sima mRNA (Figure 5C). Sima-driven expression of the FGF ligand bnl is a key element of the hypoxic response among non-tracheal cells [22,38,52]. The bnl^{PI} loss-of-function allele dominantly suppressed both the 5053A->agoΔF VLM12 phenotype (Table 3), from 9.54±0.29 (n = 50) to 6.34±0.28 branches (n = 54, p = 5.99×10^{-11}) and the ago^{AX-7}11 excess branching phenotype (Table 2), from 39.5±1.59 (n = 34) to 28.4±1.80 branches per LH cell (n = 39, p = 1.75×10^{-5}). In parallel, qRT-PCR detected an ~50% upregulation of bnl transcription in body wall muscle of ago^{AX-7}11 larvae relative to control muscle (Figure 5C). Previous studies using a genomic duplication of the bnl locus have demonstrated that a similar 50% increase in bnl gene-dosage is sufficient to elicit excess tracheal terminal cell branching [38]. Thus reduced ago function in body wall muscle is associated with ectopic expression of the dHIF target dLDH, increased levels of the bnl mRNA, and a genetic dependence on sima and bnl.

**ago acts with dVHL to restrict tracheal terminal branching**

The data above suggests that ago alleles might exhibit functional interactions with components of the Fga/dVHL pathway, which controls Sima stability and activity in vivo [21–23,53,54]. A previously characterized dVHL RNAi knockdown transgene (dVHLi) [48] was used with the 5053A->Gal4 driver to reduce dVHL expression in VLM12. Consistent with the role of dVHL upstream of sima, the 5053A->dVHli genotype showed an increase in terminal branching relative to a non-specific RNAi control (Figure 6A, and Table 3) (5.28±0.61a vs 7.48±0.21b, n = 34, p = 1.75×10^{-5}). However, dVHLi and agoΔF transgenes were then co-expressed with 5053A->Gal4 to determine their ability to enhance VLM12 tracheogenic activity (Figure 6C–6D). The 5053A->agoΔF,dVHli compound genotype shows a synergistic increase in the number of branches that terminate on VLM12 (Table 3), but also leads to a phenotype not seen in either individual genotype: whereas expression of agoΔF or dVHLi individually increase terminal branching of LF and LH onto VLM12, the agoΔF+dVHLi combination also recruits ectopic branches from the LG lateral terminal cell (as seen in the two different focal planes of a single agoΔF+dVHLi-expressing VLM12 muscle; Figure 6C–6D) which normally bypasses VLM12. This ectopic LG recruitment phenotype occurs in approximately 10% of agoΔF+dVHLi VLM12 muscles and is also observed upon 5053A->Gal4 driven expression of bnl [38] or sima (data not shown). Thus dVHLi and ago are individually required to restrict the ability of muscle cells to recruit new branch growth, and combined reduction of ago and dVHLi activity leads to increased tracheogenic signals emanating from body wall muscle.

To further define the relationship between ago and dVHL in terminal branching, transgenes expressing each factor were tested

---

**Table 3. Number of tracheal terminal branches terminating on VLM12.**

<table>
<thead>
<tr>
<th>Genotype</th>
<th># branches (± SEM)</th>
<th>n</th>
</tr>
</thead>
<tbody>
<tr>
<td>5053A-Gal4:UAS-nlsGFP,UAS-ago.sff</td>
<td>5.11±0.16a</td>
<td>54</td>
</tr>
<tr>
<td>5053A-Gal4:UAS-nlsGFP,UAS-ago.sff</td>
<td>9.54±0.29a</td>
<td>50</td>
</tr>
<tr>
<td>5053A-Gal4:UAS-nlsGFP,UAS-ago.sff</td>
<td>4.97±0.25</td>
<td>31</td>
</tr>
<tr>
<td>5053A-Gal4:UAS-nlsGFP,UAS-dMyc</td>
<td>4.86±0.25</td>
<td>50</td>
</tr>
<tr>
<td>5053A-Gal4:UAS-nlsGFP,UAS-CycE</td>
<td>7.39±0.49b</td>
<td>18</td>
</tr>
<tr>
<td>5053A-Gal4:UAS-nlsGFP,UAS-N</td>
<td>4.27±0.41</td>
<td>15</td>
</tr>
<tr>
<td>5053A-Gal4:UAS-nlsGFP-UAS-ago.sff,UAS-vgRNAi,UAS-bnlP1</td>
<td>6.54±0.28</td>
<td>54</td>
</tr>
<tr>
<td>5053A-Gal4:UAS-nlsGFP-UAS-Ago[Adf]R</td>
<td>5.28±0.20</td>
<td>40</td>
</tr>
<tr>
<td>5053A-Gal4:UAS-nlsGFP-UAS-dVHLRNAi,UAS-ago.sff</td>
<td>7.48±0.21a</td>
<td>89</td>
</tr>
<tr>
<td>5053A-Gal4:UAS-nlsGFP-UAS-sima</td>
<td>13.67±0.61</td>
<td>48</td>
</tr>
<tr>
<td>5053A-Gal4:UAS-nlsGFP-UAS-sima</td>
<td>11.42±0.36</td>
<td>52</td>
</tr>
<tr>
<td>5053A-Gal4:UAS-nlsGFP-UAS-dVHLRNAi</td>
<td>6.60±0.25</td>
<td>55</td>
</tr>
<tr>
<td>5053A-Gal4:UAS-nlsGFP-UAS-dVHLRNAi,UAS-ago</td>
<td>6.29±0.22</td>
<td>52</td>
</tr>
</tbody>
</table>

p<0.001 relative to 5053A-Gal4:UAS-nlsGFP.

<table>
<thead>
<tr>
<th>Genotype</th>
<th>VLM12 size (pixels ± SEM)</th>
<th>N</th>
</tr>
</thead>
<tbody>
<tr>
<td>5053A-Gal4:UAS-nlsGFP</td>
<td>5811.6±186.60</td>
<td>22</td>
</tr>
<tr>
<td>5053A-Gal4:UAS-nlsGFP,UAS-ago.sff</td>
<td>5585.3±134.00</td>
<td>25</td>
</tr>
<tr>
<td>5053A-Gal4:UAS-nlsGFP-UAS-dMyc</td>
<td>7470.7±262.00b</td>
<td>22</td>
</tr>
</tbody>
</table>

a Size calculated by pixel counts using Photoshop

b p<1.0×10^{-4} relative to 5053A-Gal4:UAS-nlsGFP

doic:10.1371/journal.pgen.1003314.0004
for rescue of VLM12-branching phenotypes produced by reducing the function of the other (Table 3). Expression of wild type dVHL led to a 66% suppression of the agoΔF branching phenotype (p = 6.55 × 10⁻¹²); reciprocally, over-expression of wild type ago showed a 54% suppression of the dVHL branching phenotype (p = 2.73 × 10⁻⁵). Thus, each gene can to some degree ameliorate non-autonomous branching phenotypes produced by loss of the other in the VLM12 segment.

Ago controls transcriptional and organisal responses to hypoxia

In view of the genetic and molecular links between ago, sima, dLDH, and dVHL, the organism-wide transcriptional response to hypoxia was examined in ago mutant animals. Drosophila respond to varying degrees of hypoxia by driving transcription of distinct sets of target genes at differing oxygen concentrations, including those involved in metabolic adaptation and survival in low oxygen [31,32]. A subset of hypoxia-inducible genes was selected for this analysis based on their differential transcription in hypoxic adult Drosophila [31] and predicted links to known mechanisms of the hypoxic response. These included dLDH, which plays a role in the metabolic switch to high flux glycolysis [reviewed in 55,56], lyl oxidase (los), a HIF target in mammalian cells that plays a role in hypoxia-induced changes in cell adhesion [57,50] and vascular remodeling [59], and dHIG1 (CG11825), the Drosophila homolog of Hypoxia Induced Gene-1 (HIG1), which is induced by HIF and promotes cell survival [60]. qRT-PCR analysis was carried out for each of these genes under conditions of decreasing environmental oxygen (21%, 5%, 0.5%) in whole control larvae or whole agoΔF larvae (Figure 7A–7B). We find that each of these genes is differentially induced in hypoxia in a manner consistent with findings in adult Drosophila [31] and can be ectopically induced by the agoΔF allele. dLDH is minimally transcribed in normoxic control larva, and with progressively higher transcription as the oxygen level falls (1.6 and 2.7-fold increases in 5% and 0.5% O₂, respectively, Figure 7A), confirming that dLDH transcription increases with increasing dHIF activity. In agoΔF homozygous animals, dLDH expression is increased 8.1-fold in whole normoxic larvae (this lower fold induction in the whole larva relative to the ~27-fold enrichment seen in dissected body wall muscle in Figure 5C is presumably a reflection of the tissue-specific nature of the agoΔF allele), and is increased approximately 14-fold in agoΔF/ΔF larva relative to control larva at both 5% and 0.5% O₂ (Figure 7B, top panel). Thus ago restricts dLDH expression across a broad range of oxygen concentrations. The loc gene is normally only up-regulated in whole control larva by strong hypoxia (4.4-fold induction at 0.5% O₂, Figure 7B). The agoΔF allele leads to a 2.2-fold increase in loc transcription in normoxia, and loc transcription reaches near maximal levels at 5% O₂; the 3.4-fold induction seen in ago mutants in 5% O₂ is not significantly different from that seen in control larva at 0.5% O₂ (Figure 7B, middle panel). This pattern suggests that the loc promoter is induced by levels of dHIF activity achieved in moderate hypoxic conditions, and that this threshold is more easily reached in ago mutants. The dHIG1 gene displays a more exaggerated version of the loc response pattern: dHIG1 mRNA levels are only induced strongly (19.9-fold in whole control larva by 0.5% O₂ (Figure 7A); the agoΔF allele is not sufficient to drive ectopic dHIG1 transcription in normoxic conditions but it is sufficient to sensitize the dHIG1 promoter to reduced O₂ levels such that maximal dHIG1 expression is now achieved at a ten-fold higher O₂ concentration than normal (Figure 7B, bottom panel). In addition to dLDH, loc, and dHIG1, three other genes also induced by hypoxia, hairy, amy-p and thr genes [31], are also moderately up-regulated in normoxic agoΔF mutant larvae (Table S1). Reducing ago activity is thus sufficient to alter the threshold required to drive expression of multiple hypoxia-inducible genes.
Adult *Drosophila* respond to prolonged periods of oxygen deprivation by entering into a state of hypoxic stupor characterized by inactivity and reduced oxygen consumption [34]. Many mutations have been identified that slow this hypoxic recovery [32,33,35], but few mutations have been described that enhance it. Under our standard laboratory conditions, control adult flies enter stupor after approximately fifteen to twenty minutes in a 0.5% O₂ environment and remain unconscious until re-oxygenation. We assayed control +/+ adults, ago⁻⁻⁻⁷/+ adults, and adults trans-heterozygous for the ago⁻⁻⁻⁷ allele and the ago hypomorphlic allele EP(3)1135 (BDSC) for recovery time following acute hypoxia (1 hour at 0.5% O₂) (Figure 7C). ago⁻⁻⁻⁷/EP(3)1135 flies display no obvious developmental phenotypes and enter into hypoxic stupor at the same rate as control flies (data not shown); however, they recover significantly faster than either control +/+ or ago⁻⁻⁻⁷/+ adults. Linear regression analysis indicates that the time for 50% recovery is reduced from 4.5±0.75 minutes in control +/+ flies, to 1.4±0.16 minutes in ago⁻⁻⁻⁷/EP(3)1135 flies (p = 0.0015). The ago⁻⁻⁻⁷/EP(3)1135 population also reaches 100% recovery after 10 minutes of re-oxygenation, whereas neither the control +/+ or ago⁻⁻⁻⁷/+ populations achieved 100% recovery by the end of the 15 minute measurement period (data not shown). Thus, the genetic evidence of a role for ago as a regulator of dHIF-regulated branching in the larval tracheal arbor is paralleled at the organismal level by an enhanced transcriptional sensitivity to hypoxia and an increased ability of flies to recover from a transient hypoxic challenge.

**Ago associates with Sima and suppresses Sima levels**

To test the molecular relationship between Sima and Ago, Sima levels were assessed in two ways: by immunofluorescent staining of VLM12 muscles expressing the *UAS-agoΔF* transgene and by Western blotting of lysates of ago⁻⁻⁻⁷ larval (Figure 8). Fluorescence microscopy confirms that a previously described anti-Sima antibody [24] detects high levels of transgenically expressed Sima in the VLM12 nuclei of ago⁻⁻⁻⁷-sima muscles, and that endogenous Sima is not readily detectable by this method of analysis in the nuclei of adjacent non-transgenic muscles (Figure 8A). Following expression of the agoΔF dominant-negative transgene (5053ΔΔ-agoΔF), a fraction of VLM12 nuclei accumulate anti-Sima reactive epitopes (see arrows, Figure 8B). This same anti-Sima antibody detects elevated levels of an ~110 kD molecular weight band in ago⁻⁻⁻⁷ filleted 3rd instar pelt relative to *wt* control pelt (Figure 8C). This ~110 kD band is absent in lysates of *sima*⁰⁷⁰⁰⁷ larval (Figure 8D, lane 1 vs. 2), and is specifically enriched in precipitates of an anti-Ago polyclonal antibody from lysates of hypoxic larvae (Figure 8D, lane 5). Collectively, these molecular data indicate that Ago can associate with Sima in larval lysates, and that Ago limits Sima levels in developing tissues.

**Discussion**

The selective stabilization of the Sima/HIF–1α transcription factor in hypoxia plays a key role in the response of metazoan organisms to low oxygen concentrations by its ability to induce a program of hypoxia-specific gene expression [reviewed in 2]. Evidence suggests that in *Drosophila*, Sima plays a dual role in the post-mitotic growth of tracheal terminal branch cells toward hypoxic peripheral tissues by acting within both the ‘signaling’ hypoxic peripheral cells and in the ‘responsive’ terminal tips cells [reviewed in 37].

Our data implicate the Ago-SCF ubiquitin ligase as a required regulator of Sima during hypoxia sensing in peripheral cells, but do not rule out an additional role for Ago within tracheal terminal tip cells which contributes to their ectopic branching in ago mutant larvae (see below). Phenotypes produced by muscle-specific expression of an ago dominant-negative allele, or by a genomic allele that specifically affects ago expression in peripheral tissues, are phenocopied by overexpression of Sima (this study) or the FGF homolog Bnl [38]. These non-cell autonomous effects of ago alleles on terminal branching are accompanied by a strong induction in peripheral tissues of the dHIF target *dLDH*, and can be dominantly suppressed by an allele of *sima*, ago alleles induce expression of a set of dHIF-inducible hypoxia-response genes in normoxia that includes *dLDH*, and this is paralleled at the organismal level by an enhanced ability of ago mutant flies to the recover from hypoxic stupor. ago alleles are thus among the first
genetic alterations shown to enhance the recovery of adult *Drosophila* from hypoxic exposure. Within larval muscle, ago appears to inhibit sima in parallel to dVHL, which targets the Sima/HIF–1α protein for constitutive degradation in normoxia [reviewed in 3]. Consistent with this, we find evidence that Ago can associate with Sima and limits its levels *in vivo*. Collectively, these data significantly expand the known role of Ago in organism development by demonstrating that it is required in an apparently novel pathway that collaborates with dVHL to inhibit Sima-regulated hypoxic gene expression in peripheral tissues.

Though the work presented here focuses on the ‘tracheo-attractant’ effects of reducing ago expression in body wall muscle, this may be just one manifestation of roles Ago plays in controlling hypoxia-regulated gene expression. Indeed, reducing ago function has a quantitatively stronger effect on terminal branching than a genomic duplication of the *bnl* locus [38], suggesting either that ago also acts within tracheal cells to limit branching [as in 47,48] or that a larger set of dHIF target genes contribute to the effect. Consistent with this latter hypothesis, normoxic ago mutant larvae display ectopic induction of hypoxia-responsive metabolic genes such as *dLDH*, *lox*, *hairy*, *amy-p* and *thor*. Based on this profile, it appears that ago mutant larvae reared in normoxia elevate expression of *bnl* but also engage a metabolic switch to high-flux glycolysis that is characteristic of hypoxic cells [32,33,35,36,61]. Future studies will be required to assess the full effect of these transcriptional changes on the behavior of terminal tracheal cells and the tissues into which they project.

In wild type animals, the transcriptional response of cells to hypoxia is graded such that different target genes are induced across a range of environmental O2 concentrations [31]. In ago mutants, this differential induction is largely abolished such that expression of genes such as *lox* and *dHIG1* is virtually indistinguishable at 5% and 0.5% O2. Thus, ago appears to be required both for inhibition of hypoxia-inducible genes in normoxia and for the graded expression of hypoxia-inducible genes under variable levels of oxygen deprivation. We hypothesize that this graded sensitivity is normally a product of the interaction between the Ago and Fga/dVHL regulatory mechanisms. The HPH/VHL pathway has been demonstrated to act in a graded manner, such that it degrades HIF–1α efficiently in normoxia, but is progressively less efficient as the oxygen concentration drops [62]. This leads to a gradient of HIF activity that is presumably required for the differential induction of target genes. We hypothesize that ago acts in parallel to dVHL to dampen Sima/HIF-1 activity across a range O2 concentrations, and that Ago may function as a dHIF regulatory mechanism at very low O2 concentrations in which...
the HPH/dVHL pathway is hypothesized to be inactive [62].

Thus, the absence of Ago allows a mild hypoxic stimulus (~e.g. 5% O₂) to be translated into levels of dHIF-dependent gene expression that would normally only result from much stronger hypoxic exposure. The data presented here support this prediction, with the end result that the transcriptional response profile of hypoxia-responsive genes in ago mutant larvae is shifted toward induction by more mild stimuli.

The molecular mechanism(s) underlying the genetic relationship between ago and sima in tracheal branching appears to involve a physical association of their encoded proteins that modulates Sima levels. Given that Ago is a ubiquitin ligase specificity factor, these data are consistent with a model in which Ago supports Sima polyubiquitination and turnover. Recent studies have identified the human Ago ortholog Fbw7 as a HIF-1α interacting factor and have proposed that Fbw7 promotes HIF-1α turnover following GSK3β phosphorylation in cultured cells [45,46]. Phenotypic predictions made by this molecular model appear to be confirmed by the ago terminal cell branching phenotypes documented here. Intriguingly, RNAi depletion of GSK3β/shaggy or a proteasome subunit in VLM12 also elevates the number of tracheal branches that terminate on this muscle (Table S2). However Fbw7 is implicated in the proteolytic destruction of two transcription factors, the Notch intracellular domain (NICD) [reviewed in 51] and sterol-regulatory enhancer binding protein (SREBP) [63], that indirectly modulate HIF-dependent hypoxic gene expression in eukaryotic cells [64,65]. Ago could thus theoretically influence hypoxic gene expression via these paths as well. Future biochemical studies will be required to clarify the full range of Ago molecular targets that contribute to its role in hypoxic gene expression.

The well-studied anti-proliferative role of ago is conserved in its human ortholog Fbw7, which is mutationally inactivated in a wide spectrum of primary human cancers [reviewed in 51]. Some cancer cells engage a program of gene expression that supports a switch to high-flux glycolysis (a phenomenon termed ‘Warburg effect’ [26]) and are more resistant to transient hypoxia than normal cells [reviewed in 1]. Both of these properties can now, to some degree, also be associated with ago loss in Drosophila. In view of the functional conservation between SCF-Ago and SCF-Fbw7 in degradation of shared oncogetic targets [49,50] and the proposed role of Ago/Fbw7 in Sima HIF-1α turnover [this study and 45,46], our data raise the interesting possibility that sensitization to mild hypoxia may be a feature of Fbw7 mutations in vertebrates as well. If so, then tumor suppressive properties of Fbw7 may derive in part from its established anti-proliferative role and in part due to modulation of HIF-regulated angiogenic and metabolic pathways.

Materials and Methods

Stocks, genetics, and statistics

The FRT80B and w<sup>1118</sup> strains were used as wild type controls. The ago<sup>k7</sup> and ago<sup>°</sup> alleles have been previously described [49]. The ago<sup>k7</sup> allele was identified as an imprecise excision of the ago<sup>pt31135</sup> transposon. Alleles used in this study: bnl<sup>°</sup>, sima<sup>°</sup>, ago<sup>pt31135</sup>, ago<sup>°</sup> (all from the Bloomington Drosophila Stock Center) and 1-ex1-1 [66]. The following transgenes were also used: UAS-agoΔF and UAS-agoΔ [47]; UAS-Cy3-E, UAS-dMyc, UAS-N, UAS-n-GFP (all from the Bloomington Drosophila Stock Center), UAS-ub [67], UAS-sima [24], UAS-dVHL [21], UAS-Adyf<sup>RasN</sup> and UAS-arg<sup>RasN</sup> (Vienna Drosophila RNAi Center), UAS-dVHL<sup>RasN</sup> [48], hs-Gal4, and 5035A-Gal4 (from the Bloomington Drosophila Stock Center). Statistical comparisons were made using Student’s t-Test (Microsoft Excel) with the indicated significance levels.

Hypoxia treatments

Hypoxia treatments were performed in a sealed Modular incubator chamber (Billups-Rothenberg Inc., Del Mar, CA) with separate gas intake and exhaust openings. Internal O₂ concentration was measured with an electronic O₂ sensor (OX-01, RKI Instruments, Inc., Union City, CA). To assay recovery from hypoxia, 5–7 day old adult flies were put into plain glass tubes in groups of 9–15. The flies were then placed into the hypoxia chamber at 0.5% O₂ for one hour and then removed to normoxia. Following hypoxic treatment, >99% of the flies (178 of 179) had fallen into hypoxic stupor. Recovery time was defined as the time required for each individual fly to resume walking following re-oxygenation.

Reverse transcription and quantitative real-time PCR (qRT–PCR)

Total RNA was isolated from dissected third instar larval body wall muscles. cDNA was reverse-transcribed using random hexamer primers (Invitrogen) with Superscript II Reverse Transcriptase (Invitrogen). dVHL and β-tubulin transcripts were then amplified with gene-specific primers. For quantification of mRNA levels, total RNA was isolated from whole third instar larvae or dissected larval tissues and reverse transcribed as described above. Levels of Arp87c, ago-RA, -RB and -RC, dLDH, sima, bnl, lhx, hairy, dHIG1, thr and amy-p were then assayed with gene-specific primers using the SYBR green method of quantitative real-time PCR on a Roche LightCycler 480 machine. Transcript abundance was normalized to levels of Arp87c as in [31].

Imaging of third instar larval trachea

To image the larval tracheal system, third instar larvae were dissected in cold PBS and fixed in 4% paraformaldehyde. Air-filled tracheal branches were imaged using bright-field microscopy, and assembled using Photomerge (Adobe Photoshop CS).

Immunohistochemistry, Western blotting, and immunoprecipitation

Third instar larvae were dissected in cold PBS, fixed in 4% paraformaldehyde and incubated with guinea pig anti-Cyclin E (1:500) or rabbit anti-Sima (1:1000). Secondary antibodies (anti-guinea pig conjugated to Cy3 or anti-rabbit conjugated Cy5) were used as recommended (Jackson ImmunoResearch). To assess Sima protein levels in third instar larvae, larval pelt extracts were prepared in sample buffer and resolved on 7.5% SDS-PAGE prior to Western blotting with rabbit anti-Sima (1:1000) [24] and developed with anti-rabbit HRP (1:1000; Jackson ImmunoResearch). Whole larval extracts were immunoprecipitated with guinea pig anti-Ago polyclonal sera (1:1000) [47] prior to immunoblotting with anti-Sima antibody.

Supporting Information

Figure S1 Loss of ago does not deregulate Cyclin E levels in body wall muscle cells. Comparison of Cyclin E levels in VLM12 and VLM13 in 5035A-Gal4;UAS-GFP,UAS-agoΔF larvae. Larvae were stained with α-Cyclin E antiserum (red). GFP marks VLM12 (green).

(TIF)

Table S1 Relative induction of hypoxia-responsive genes in normoxic ago larvae. Relative levels of mRNAs of the indicated genes normalized to the level of each mRNA in wt control larvae. Experiments were done in triplicate. P-values provided for each gene. (DOCX)
Table S2  Number of tracheal terminal branches terminating on VLM12. Number of tracheal terminal branches terminating on the VLM12 muscle segment in the indicated genotypes. P-values are indicated.

Acknowledgments

We apologize to those whose work could not be cited due to space constraints. We thank S. Cresko, P. Wappner, M. Krasnow, and D. Andrew for gifts of stocks and reagents. We also thank the Developmental Studies Hybridoma Bank and the Bloomington Drosophila Stock Center for additional reagents.

Author Contributions

Conceived and designed the experiments: KHM NTM. Performed the experiments: NTM. Analyzed the data: KHM NTM. Contributed reagents/materials/analysis tools: KHM NTM. Wrote the paper: KHM NTM.

References


